News & Updates
Filter by Specialty:
Novel tri-agonist confers significant gains for MASLD patients
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
HBV vaccine improves survival of patients with chronic liver disease
Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.
HBV vaccine improves survival of patients with chronic liver disease
22 Nov 2023
Modified PDT on par with isotretinoin therapy for moderate-to-severe acne vulgaris
The modified red light 5-aminolevulinic acid photodynamic therapy (M-PDT) delivers a faster onset of improvement, similar overall efficacy, good tolerability, and comparable durability of response when compared with low-dose isotretinoin (ISO) therapy in patients with moderate-to-severe acne vulgaris, reports a study.
Modified PDT on par with isotretinoin therapy for moderate-to-severe acne vulgaris
22 Nov 2023
More evidence support ticagrelor monotherapy after <1-month DAPT in ACS
Dropping aspirin after <1 month of dual antiplatelet therapy (DAPT) with ticagrelor is superior to continuing both drugs through 12 months in patients with acute coronary syndrome (ACS) implanted with drug-eluting stents in the T-PASS trial.